TITLE

Mitochondrial DNA deletions in coronary artery bypass grafting patients

AUTHOR(S)
Levitsky, Sidney; Laurikka, Jari; Stewart, Robert D.; Campos, Christian T.; Lahey, Steven J.; McCully, James D.
PUB. DATE
November 2003
SOURCE
European Journal of Cardio-Thoracic Surgery;Nov2003, Vol. 24 Issue 5, p777
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: Mitochondrial DNA (mitoDNA) deletions have been shown to increase with aging and ischemia and have been suggested to contribute to myocardial dysfunction. The purpose of this study was to determine the prevalence and specificity of mitoDNA deletions in coronary artery bypass patients. Methods: Right atrial appendix tissue from 51 cardiac surgical patients (30–93 years; mean 64±14 years) was obtained during cardiopulmonary bypass cannulation (Control), just prior to the removal of the venous cannula (Ischemia, 169±38 min) and following removal of the cannula (Reperfusion) and used for polymerase chain reaction (PCR) and sequence analysis. Results: A novel mitoDNA deletion (approximately 7.3 kb, mitoDNA7.3) was found in three unrelated, male patients (53, 67, 75 years old). All mitoDNA7.3 deletion breakpoints were found downstream of the ATP synthase 8 genes and at the 3′ end of the cytochrome b genes. The prevalence of the mitoDNA7.3 deletion was significantly increased (P<0.05) following ischemia and reperfusion. Clinical data indicated that postoperative left ventricular ejection fraction was lower (38.3 vs. 46.4%), and the incidence of previous myocardial infarction higher (1.7 vs. 0.6) in patients exhibiting mitoDNA deletions. Conclusion: Our results reveal a novel mitochondrial DNA deletion occurring within the genome region coding for the mitochondrial genes of oxidative phosphorylation that is significantly increased during ischemia and reperfusion. The incidence and prevalence of mitoDNA7.3 deletions in patients with clinical indications of poor recovery suggests that mitoDNA7.3 deletions may provide an important indicator to surgical outcome in the cardiac surgical patient.
ACCESSION #
11175684

 

Related Articles

  • Salvia miltiorrhiza treatment during early reperfusion reduced postischemic myocardial injury in the rat. Ruqiong Nie; Rui Xia; Xingwu Zhong; Zhengyuan Xia // Canadian Journal of Physiology & Pharmacology;Oct2007, Vol. 85 Issue 10, p1012 

    Oxidative stress may play a causative role in myocardial ischemia�reperfusion injury. However, it is a relatively understudied aspect regarding an optimal timing of antioxidant intervention during ischemia�reperfusion. The present study investigates the effect of different treatment...

  • Inhibition of sPLA2-IIA, C-reactive Protein or Complement: New Therapy for Patients with Acute Myocardial Infarction? Krijnen, Paul A. J.; Meischl, Christof; Nijmeijer, Remco; Visser, Cees A.; Hack, C. Erik; Niessen, Hans W. M. // Cardiovascular & Haematological Disorders - Drug Targets;Jun2006, Vol. 6 Issue 2, p111 

    Reperfusion of ischemic myocardium after acute myocardial infarction (AMI) induces a local activation of inflammatory reactions that results in ischemia/reperfusion (I/R)-injury. I/R-injury contributes considerably to the total cell damage in the heart after AMI. Secretory phospolipase A2-IIA...

  • Management of the no-reflow phenomenon. Margetić, Eduard // Cardiologia Croatica;Mar/Apr2013, Vol. 8 Issue 3/4, p119 

    Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy for treating acute ST-segment elevation myocardial infarction (STEMI). The main goals are to restore epicardial infarct-related artery (IRA) patency and achieve microvascular reperfusion as early as possible,...

  • Reduction of infarct size by gentle reperfusion without activation of reperfusion injury salvage kinases in pigs. Musiolik, Judith; Caster, Patrick van; Skyschally, Andreas; Boengler, Kerstin; Gres, Petra; Schulz, Rainer; Heusch, Gerd // Cardiovascular Research;Jan2010, Vol. 85 Issue 1, p110 

    Aims: Reperfusion is mandatory to salvage ischaemic myocardium from infarction, but also induces additional reperfusion injury and contributes to infarct size (IS). Gentle reperfusion (GR) has been proposed to attenuate reperfusion injury, but this remains contentious. We now investigated...

  • Hypothermia during reperfusion does not reduce myocardial infarct size in pigs. Maeng, Michael; Mortensen, Ulrik M.; Kristensen, Jens; Kristiansen, Steen B.; Andersen, Henning R. // Basic Research in Cardiology;Jan2006, Vol. 101 Issue 1, p61 

    We previously described a method for regional myocardial cooling that reaches the target temperature within 4 min. The present study evaluated whether this method for regional myocardial cooling during reperfusion reduces myocardial infarct size (IS) in 75–kg pigs. Myocardial infarction...

  • Adenosine as an Adjunct Therapy in ST Elevation Myocardial Infarction Patients: Myth or Truth? Kassimis, George; Davlouros, Periklis; Patel, Niket; Maria, Gianluigi; Kallistratos, Manolis; Kharbanda, Rajesh; Manolis, Athanasios; Alexopoulos, Dimitrios; Banning, Adrian // Cardiovascular Drugs & Therapy;Oct2015, Vol. 29 Issue 5, p481 

    Early reperfusion represents the key strategy in ST elevation myocardial infarction. However, reperfusion may induce myocardial damage due to the reperfusion myocardial injury, compromising the full potential of reperfusion therapy and accounting for unfavourable results in high risk patients....

  • Persistent Oxidative Stress after Myocardial Infarction Treated by Percutaneous Coronary Intervention. NIKOLIC-HEITZLER, VJERAN; RABUZIN, FILIP; TATZBER, FRANZ; VRKIC, NADA; BULJ, NIKOLA; BOROVIC, SUZANA; WONISCH, WILLIBALD; SUNKO, BRANKA MAZUL; ZARKOVIC, NEVEN // Tohoku Journal of Experimental Medicine;Nov2006, Vol. 210 Issue 3, p247 

    Acute myocardial infarction causing cardiac ischemia is responsible for the majority of cardiac related deaths. Medical interventions that ensure rapid reperfusion, such as percutaneous coronary intervention, are aimed to allow myocardial re-oxygenation. However, this generates reactive oxygen...

  • Adiponectin protects against myocardial ischaemia-reperfusion injury via AMP-activated protein kinase, Akt, and nitric oxide. Gonon, Adrian T.; Widegren, Ulrika; Bulhak, Aliaksandr; Salehzadeh, Firoozeh; Persson, Jonas; Sjöquist, Per-Ove; Pernow, John // Cardiovascular Research;Apr2008, Vol. 78 Issue 1, p116 

    Aims: Cardiovascular disease and type 2 diabetes mellitus are associated with low plasma concentration of adiponectin. The aim of this study was to investigate whether adiponectin exerts cardioprotective effects during myocardial ischaemia-reperfusion and whether this effect is related to the...

  • Potential of Microvascular Reperfusion with Adjunctive Pharmacological Intervention: Its Impact on Myocardial Perfusion and Functional Outcomes in Patients with Acute Myocardial Infarction. Taniyama, Y.; Ito, H.; Morishita, R.; Ogihara, T. // Drugs;Feb2001, Vol. 61 Issue 4, p437 

    One of the major limitations of reperfusion therapy in acute myocardial infarction (AMI) is the presentation of no-reflow phenomenon. In 25 to 30% of patients with AMI, myocardial blood flow is occasionally profoundly reduced, even after coronary recanalisation, because of microvascular...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics